Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: cabazitaxel

« Back to Dashboard
Cabazitaxel is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and seventy-nine patent family members in fifty-seven countries.

There are twelve drug master file entries for cabazitaxel. One supplier is listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: cabazitaxel

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Drug Master File Entries: see list12
Suppliers / Packaging: see list1

Tentative approvals for CABAZITAXEL

Applicant Application No. Form Dosage
<disabled><disabled>INJECTABLE;INJECTION20MG/ML(60MG/3ML)
<disabled><disabled>INJECTABLE;INJECTION40MG/4ML
<disabled><disabled>INJECTABLE;INJECTION60MG/6ML

Clinical Trials for: cabazitaxel

Cabazitaxel - PF Induction Chemotherapy
Status: Completed Condition: Squamous Cell Carcinoma of the Head and Neck

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
Status: Recruiting Condition: Urothelium Transitional Cell Carcinoma

Study of Weekly Cabazitaxel for Advanced Prostate Cancer
Status: Active, not recruiting Condition: Hormone Refractory Prostate Cancer

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Status: Withdrawn Condition: Castrate-resistant Metastatic Prostate Cancer

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Status: Terminated Condition: Prostate Cancer; Prostatic Neoplasms

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYes5,847,170<disabled>YY <disabled>
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYes8,927,592<disabled> <disabled>
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYes6,372,780<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: cabazitaxel

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 20105,438,072<disabled>
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 20105,698,582<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: cabazitaxel

Country Document Number Publication Date
Japan2007505866Mar 15, 2007
Canada2214319Oct 03, 1996
Georgia, Republic ofP20002211May 10, 2000
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc